Orchestra BioMed Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by Orchestra BioMed Holdings, Inc. on June 20, 2024. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on The Nasdaq Global Market under the symbol OBIO.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting. A total of 28,647,942 shares were represented out of 35,786,497 shares entitled to vote.
- Proposal 1: Election of Directors
- Eric A. Rose, M.D.: Elected with 22,471,631 votes for, 2,170,666 votes withheld, and 4,005,645 broker non-votes.
- Jason Aryeh: Elected with 24,004,640 votes for, 637,657 votes withheld, and 4,005,645 broker non-votes.
- Both nominees were elected to serve as Class I directors until the 2027 annual meeting.
- Proposal 2: Ratification of Independent Registered Public Accounting Firm
- The appointment of Ernst & Young LLP for the fiscal year ending December 31, 2024, was approved.
- Votes: 28,620,141 For, 25,400 Against, 2,401 Abstentions, and 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that the two Class I director nominees (Eric A. Rose, M.D. and Jason Aryeh) were successfully elected.
- Verification that Ernst & Young LLP was ratified as the independent auditor for the 2024 fiscal year.
- Review of the definitive proxy statement filed on April 30, 2024, for detailed background on the proposals.